Relypsa Submits New Drug Application To U.S. FDA Seeking Approval For Patiromer For Oral Suspension To Treat Hyperkalemia
October 22, 2014 at 08:03 AM EDT
Relypsa, Inc. (Nasdaq: RLYP), today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug ...
